BACKGROUND: New treatments for atrial fibrillation patients have been shown to be effective at reducing subsequent vascular event recurrence. However, there are few data on stroke costs in atrial fibrillation patients to allow the cost-effectiveness of these treatments to be assessed. AIMS: Using data from a population-based study, we assessed the acute and long-term costs of stroke in atrial fibrillation patients. METHODS: Health-care costs one-year before and five-years after stroke were obtained from a large population-based study (Oxford Vascular study). Costs were assessed for the three-months poststroke (acute period) and annually thereafter (postacute period). Annual postacute costs were compared with annual baseline costs. Based on patients' living arrangements, costs of institutionalization after the event were included. RESULTS: A total of 191 strokes occurred in 153 patients with known prior atrial fibrillation. Mean health-care costs after stroke were £10 413 (standard deviation 15 105) in the acute phase, with annual postacute health-care costs nonsignificantly smaller than those incurred before the event (£2400 vs. £3356, respectively; P = 0·198). However, for the 136 strokes surviving past the 90-day acute period, costs were nonsignificantly higher than those incurred in the year before the event (£3370 vs. £2566, respectively; P = 0·333). After stroke, 25 (13%) patients were newly admitted into long-term warden, nursing, or residential care, resulting in annual costs of £6880 (standard deviation 15 600) averaged across the 136 stroke cases surviving past the acute period. CONCLUSIONS: Although annual post acute phase hospital and primary health-care costs in stroke patients with prior atrial fibrillation were not significantly different to those incurred before the stroke, long-term nursing/residential care costs were substantial.
BACKGROUND: New treatments for atrial fibrillation patients have been shown to be effective at reducing subsequent vascular event recurrence. However, there are few data on stroke costs in atrial fibrillation patients to allow the cost-effectiveness of these treatments to be assessed. AIMS: Using data from a population-based study, we assessed the acute and long-term costs of stroke in atrial fibrillation patients. METHODS: Health-care costs one-year before and five-years after stroke were obtained from a large population-based study (Oxford Vascular study). Costs were assessed for the three-months poststroke (acute period) and annually thereafter (postacute period). Annual postacute costs were compared with annual baseline costs. Based on patients' living arrangements, costs of institutionalization after the event were included. RESULTS: A total of 191 strokes occurred in 153 patients with known prior atrial fibrillation. Mean health-care costs after stroke were £10 413 (standard deviation 15 105) in the acute phase, with annual postacute health-care costs nonsignificantly smaller than those incurred before the event (£2400 vs. £3356, respectively; P = 0·198). However, for the 136 strokes surviving past the 90-day acute period, costs were nonsignificantly higher than those incurred in the year before the event (£3370 vs. £2566, respectively; P = 0·333). After stroke, 25 (13%) patients were newly admitted into long-term warden, nursing, or residential care, resulting in annual costs of £6880 (standard deviation 15 600) averaged across the 136 stroke cases surviving past the acute period. CONCLUSIONS: Although annual post acute phase hospital and primary health-care costs in stroke patients with prior atrial fibrillation were not significantly different to those incurred before the stroke, long-term nursing/residential care costs were substantial.
Authors: Karen L Furie; Scott E Kasner; Robert J Adams; Gregory W Albers; Ruth L Bush; Susan C Fagan; Jonathan L Halperin; S Claiborne Johnston; Irene Katzan; Walter N Kernan; Pamela H Mitchell; Bruce Ovbiagele; Yuko Y Palesch; Ralph L Sacco; Lee H Schwamm; Sylvia Wassertheil-Smoller; Tanya N Turan; Deidre Wentworth Journal: Stroke Date: 2010-10-21 Impact factor: 7.914
Authors: Niamh Hannon; Elizabeth Callaly; Alan Moore; Danielle Ní Chróinín; Orla Sheehan; Michael Marnane; Aine Merwick; Lorraine Kyne; Joseph Duggan; Patricia M E McCormack; Eamon Dolan; Gloria Crispino-O'Connell; Dawn Harris; Gillian Horgan; David Williams; Peter J Kelly Journal: Stroke Date: 2011-07-21 Impact factor: 7.914
Authors: N L Cabral; A R R Gonçalves; A L Longo; C H C Moro; G Costa; C H Amaral; L A M Fonseca; J Eluf-Neto Journal: J Neurol Neurosurg Psychiatry Date: 2009-03-11 Impact factor: 10.154
Authors: P M Rothwell; A J Coull; L E Silver; J F Fairhead; M F Giles; C E Lovelock; J N E Redgrave; L M Bull; S J V Welch; F C Cuthbertson; L E Binney; S A Gutnikov; P Anslow; A P Banning; D Mant; Z Mehta Journal: Lancet Date: 2005-11-19 Impact factor: 79.321
Authors: Abdullah Pandor; Daniel Horner; Sarah Davis; Steve Goodacre; John W Stevens; Mark Clowes; Beverley J Hunt; Tim Nokes; Jonathan Keenan; Kerstin de Wit Journal: Health Technol Assess Date: 2019-12 Impact factor: 4.014
Authors: Sandeep Panikker; Joanne Lord; Julian W E Jarman; Shannon Armstrong; David G Jones; Shouvik Haldar; Charles Butcher; Habib Khan; Lilian Mantziari; Edward Nicol; Wajid Hussain; Jonathan R Clague; John P Foran; Vias Markides; Tom Wong Journal: Eur Heart J Date: 2016-03-01 Impact factor: 29.983
Authors: T I Verhoef; W K Redekop; S Langenskiold; F Kamali; M Wadelius; G Burnside; A-H Maitland-van der Zee; D A Hughes; M Pirmohamed Journal: Pharmacogenomics J Date: 2016-06-07 Impact factor: 3.550
Authors: Anuraag R Kansal; Sonja V Sorensen; Ray Gani; Paul Robinson; Feng Pan; Jonathan M Plumb; Martin R Cowie Journal: Heart Date: 2012-04 Impact factor: 5.994
Authors: Gabriel S C Yiin; Dominic P J Howard; Nicola L M Paul; Linxin Li; Ramon Luengo-Fernandez; Linda M Bull; Sarah J V Welch; Sergei A Gutnikov; Ziyah Mehta; Peter M Rothwell Journal: Circulation Date: 2014-09-10 Impact factor: 29.690